{
    "2021-05-03": [
        [
            {
                "time": "2021-04-26",
                "original_text": "Lilly Declares Second-Quarter 2021 Dividend and Announces Additional Share Repurchase Authorization",
                "features": {
                    "keywords": [
                        "Dividend",
                        "Share Repurchase",
                        "Authorization"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2021-04-27",
                "original_text": "Lilly to Commit $5 Million to Direct Relief's Fund for Health Equity",
                "features": {
                    "keywords": [
                        "Commit",
                        "$5 Million",
                        "Health Equity"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-28",
                "original_text": "The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "Eli Lilly",
                        "Merck",
                        "GlaxoSmithKline",
                        "Novartis",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}